Sanara MedTech Inc. (SMTI) FY2024 10-K Annual Report
Sanara MedTech Inc. (SMTI) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Sanara MedTech Inc. FY2024 10-K Analysis
Business Overview
- • Core business model: Developer and marketer of surgical, chronic wound, and skincare technologies with value-based care services
- • New emphasis on Tissue Health Plus segment launching first pilot in Q2 2025 for value-based wound care targeting Medicare Advantage payers
- • Strategic shift from one to two reportable segments reflecting growing focus on value-based wound care programs
- • First sales of new surgical product BIASURGE commenced November 2023, expanding surgical irrigation offerings
- • Exclusive December 2023 Tufts license for 18 collagen peptides, forming subsidiary Sanara Collagen Peptides with royalty payments to Tufts
Management Discussion & Analysis
- • Revenue and profit figures not disclosed in MD&A section
- • No segment performance details provided
- • No cash flow, buyback, dividend, or capex data included
- • Forward-looking statements present, but no specific guidance or emerging risks detailed
Risk Factors
- • Regulatory risk: FDA 510(k) clearance required for products like BIASURGE and Chemo Mouthpiece, impacting go-to-market timing
- • Macroeconomic risk: Medicare Advantage payers targeted by Tissue Health Plus segment, exposed to changes in US healthcare reimbursement policies
- • Operational risk: Reliance on third-party network of providers for Tissue Health Plus wound care programs creates delivery execution vulnerability
- • Competitive risk: Competition for surgical wound care with established firms marketing collagen and bone fusion tech including proprietary hydrolyzed collagen products
- • Financial risk: $55 million senior secured CRG Term Loan with borrowings of $30.5 million as of 2025, increasing leverage and interest obligations
Sanara MedTech Inc. FY2024 Key Financial MetricsXBRL
Revenue
$87M
▲ +33.4% YoY
Net Income
-$10M
▼ -124.6% YoY
Gross Margin
90.6%
▲ +269bp YoY
Operating Margin
-7.7%
▼ -126bp YoY
Net Margin
-11.2%
▼ -453bp YoY
ROE
-24.5%
▼ -1493bp YoY
Total Assets
$88M
▲ +19.3% YoY
EPS (Diluted)
$-1.14
▼ -119.2% YoY
Operating Cash Flow
-$23,784
▲ +99.3% YoY
Source: XBRL data from Sanara MedTech Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Sanara MedTech Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.